Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.97 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.51 |
| ▸ | HTR3B | O95264 | 3/20 | 0.51 |
| ▸ | HTR3A | P46098 | 3/20 | 0.51 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.51 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | BPTF | Q12830 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906077 | 1.00 | ADRB2 (0.97) | ADRB2HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL5585896 | 0.98 | ADRB2 (1.00) | ADRB2HTR3EHTR3BHTR3AHTR3D | |
| Tert-Butyl Formate SCHEMBL27809039 | 0.87 | ADRB2 (0.74) | ADRB2HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL23779626 | 0.84 | ADRB2 (0.70) | ADRB2ALDH1A1CYP1A2MAPK1HTT | |
| SCHEMBL12780912 | 0.84 | ADRB2 (0.70) | ADRB2ALDH1A1CYP1A2MAPK1HTT | |
| SCHEMBL12763838 | 0.81 | ADRB2 (0.67) | ADRB2CYP1A2LCATCXCR3 | |
| SCHEMBL5585596 | 0.80 | ADRB2 (0.65) | ADRB2ALDH1A1HTR2CLCATCXCR3 | |
| SCHEMBL5585785 | 0.80 | ADRB2 (0.65) | ADRB2ALDH1A1HTR2CLCATCXCR3 | |
| SCHEMBL5585598 | 0.80 | ADRB2 (0.65) | ADRB2ALDH1A1HTR2CLCATCXCR3 | |
| SCHEMBL25390151 | 0.80 | ADRB2 (0.65) | ADRB2CYP1A2CYP2C9CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114351-A1 | 5-HT2C RECEPTOR MODULATING AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE, MENTAL, COGNITIVE AND AUTOIMMUNE CNS DISORDERS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2025-04-10 | — | — | US | claimed |
| WO-2023248222-A1 | 5-HT2C RECEPTOR MODULATING AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE, MENTAL, COGNITIVE AND AUTOIMMUNE CNS DISORDERS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2023-12-28 | — | — | WO | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| US-20250114351-A1 | 5-HT2C RECEPTOR MODULATING AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE, MENTAL, COGNITIVE AND AUTOIMMUNE CNS DISORDERS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2025-04-10 | — | — | US | disclosed |
| EP-4525833-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | Increvet, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| WO-2023248222-A1 | 5-HT2C RECEPTOR MODULATING AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE, MENTAL, COGNITIVE AND AUTOIMMUNE CNS DISORDERS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023225492-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | INCREVET, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023220930-A1 | VETERINARY PHARMACEUTICAL FORMULATIONS CROSS-REFERENCES TO RELATED APPLICATIONS | INCREVET, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230372374-A1 | VETERINARY PHARMACEUTICAL FORMULATIONS | INCREVET, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220249440-A1 | MUSCLE REGENERATION PROMOTER | SATO PHARMACEUTICAL CO., LTD. (JP) | 2022-08-11 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | ADRB2 3795/4885HTR3E 1328/4885HTR3B 1701/4885 |
| US-20220249440-A1 | MUSCLE REGENERATION PROMOTER | MUSK, MYLK2, MYH2 | ADRB2 76/4885HTR3E 64/4885HTR3B 13/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | ADRB2 3018/4885HTR3E 1243/4885HTR3B 1651/4885 |
| US-20230372374-A1 | VETERINARY PHARMACEUTICAL FORMULATIONS | SLC5A2, SLC5A1, SLC2A8 | ADRB2 321/4885HTR3E 1434/4885HTR3B 1882/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | ADRB2 3495/4885HTR3E 1824/4885HTR3B 2079/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | ADRB2 3495/4885HTR3E 1824/4885HTR3B 2079/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | ADRB2 2922/4885HTR3E 1296/4885HTR3B 1479/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | ADRB2 3816/4885HTR3E 1317/4885HTR3B 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.